BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36357283)

  • 1. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
    Xie Z; Chen EC; Stahl M; Zeidan AM
    Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
    DeZern AE; Greenberg PL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
    Sauta E; Robin M; Bersanelli M; Travaglino E; Meggendorfer M; Zhao LP; Caballero Berrocal JC; Sala C; Maggioni G; Bernardi M; Di Grazia C; Vago L; Rivoli G; Borin L; D'Amico S; Tentori CA; Ubezio M; Campagna A; Russo A; Mannina D; Lanino L; Chiusolo P; Giaccone L; Voso MT; Riva M; Oliva EN; Zampini M; Riva E; Nibourel O; Bicchieri M; Bolli N; Rambaldi A; Passamonti F; Savevski V; Santoro A; Germing U; Kordasti S; Santini V; Diez-Campelo M; Sanz G; Sole F; Kern W; Platzbecker U; Ades L; Fenaux P; Haferlach T; Castellani G; Della Porta MG
    J Clin Oncol; 2023 May; 41(15):2827-2842. PubMed ID: 36930857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms.
    Polprasert C; Niparuck P; Rattanathammethee T; Kobbuaklee S; Lanamtieng T; Rojnuckarin P
    Hematology; 2022 Dec; 27(1):1301-1304. PubMed ID: 36519260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular international prognostic scoring system for myelodysplastic syndromes].
    Nagata Y
    Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
    Ball S; Komrokji RS; Sallman DA
    Leuk Lymphoma; 2022 Jun; 63(6):1281-1291. PubMed ID: 34933652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
    de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
    Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
    Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
    Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refined cytogenetic IPSS-R evaluation by the use of SNP array in a cohort of 290 MDS patients.
    Scarpelli I; Stalder VB; Tsilimidos G; Rapakko K; Costanza M; Blum S; Schoumans J
    Genes Chromosomes Cancer; 2023 Dec; 62(12):721-731. PubMed ID: 37449676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
    Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
    Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
    Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
    Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
    Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
    Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
    Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
    Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic models in myelodysplastic syndromes.
    Bejar R
    Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and risk models in myelodysplastic syndromes.
    Komrokji RS; Padron E; Lancet JE; List AF
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S295-9. PubMed ID: 24290214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.